Blake Byers is the cofounder of Newlimit, advancing lifespan extension through immune rejuvenation therapies. Holding a Stanford PhD in bioengineering, he combines deep scientific expertise with a successful venture capital background, including eight IPOs as an early-stage investor and experience at GV. His recent work focuses on reversing functional age decline in T cells, positioning him at the forefront of longevity science and biotech innovation.

‌